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Background: To investigate the association between serum glycosylated hemoglobin (HbA1c) levels and
nonalcoholic fatty liver disease (NAFLD) in an elderly Chinese population.
Methods: A cross-sectional study was performed among the 949 retired elderly employees of Zhenhai Refining
& Chemical Company Ltd., Ningbo, China.
Results: A total of 257 (27.08%) subjects fulfilled the diagnostic criteria of NAFLD, and NAFLD patients had
significantly higher serum HbA1c levels than controls (P <0.001). The prevalence of NAFLD was significantly higher
in subjects with increased serum HbA1c level (HbA1c ≥6.5%) than in those with normal range of serum HbA1c
level (51.71% vs. 25.20%; P <0.001), and the prevalence increased along with progressively higher serum HbA1c
levels (P for trend <0.001). Stepwise logistic regression analysis showed that serum HbA1c level was significantly
associated with the risk for NAFLD (odds ratio: 1.547, 95% confidence interval: 1.054 – 2.270; P =0.026).
Conclusions: Our results suggest that serum HbA1c level is associated with NAFLD, and increased serum HbA1c
level is an independent risk factor for NAFLD in elderly Chinese.
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Nonalcoholic fatty liver disease (NAFLD) has become
one of the most common chronic liver disease world-
wide, and the condition affects one in four adults in the
general population [1,2]. The spectrum of NAFLD is
wide ranging from simple steatosis through nonalcoholic
steatohepatitis (NASH) to cirrhosis [3]. Patients with
simple steatosis appear to have benign progression, while
patients with NASH may progress to cirrhosis and even
hepatocellular carcinoma [4].
NAFLD is closely associated with the metabolic syn-
drome, a cluster of metabolic abnormalities including
central obesity, hypertension, dyslipidaemia and type 2
diabetes [5,6]. The metabolic syndrome, partly through
glucose intolerance, is linearly linked with hepatic stea-
tosis, fibrosis and cirrhosis, suggesting close connection* Correspondence: xiaofu@zju.edu.cn
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reproduction in any medium, provided the orbetween glycemic level and NAFLD [7]. In addition, the
prevalence of NAFLD increases as the increase of gly-
cemic level [8]. Glycemic ranges can be assessed by
many methods, including glycosylated hemoglobin
(HbA1c). HbA1c, reflecting average glycemia over the
preceding 8 –12 weeks, is used to estimate chronic gly-
cemic levels with 6.5% as the cutoff point to diagnose
diabetes [9]. However, when it comes to HbA1c, the as-
sociation between NAFLD and glycemic levels has not
been well documented so far.
NAFLD mainly occurs among middle-aged to older
people, with a mean presentation age of 44–50 years
[10,11]. However, Koehler et al. observed that the preva-
lence of NAFLD was as high as 35.1% in the elderly [12].
Recent studies also showed that age was an independent
risk factor for NAFLD development [4,13]. A large sample
cross-sectional analysis revealed an independent associ-
ation between HbA1c level and NAFLD in predominantly
middle-aged subjects [14]. Considering serum HbA1c
level increases with age [15], middle-aged participants. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and not fully highlight the significance of HbA1c in
NAFLD. For these reasons, clarifying the association be-
tween HbA1c level and NAFLD in elderly subjects may
have significant clinical implications for the diagnosis
and prevention of NAFLD by monitoring HbA1c level.
Here, we performed a cross-sectional study to investigate
the association between HbA1c and NAFLD determined
by ultrasonography in an elderly Chinese population.
Methods
Study design and subjects
This study was conducted among retired elderly employ-
ees (age ≥65 years) of Zhenhai Refining & Chemical
Company Ltd. (Ningbo, China). All of the retired elderly
employees who attended their annual health examin-
ation during the year of 2010 were initially enrolled. The
following subjects were excluded: subjects with alcohol
consumption greater than 140 g/week for males and
70 g/week for females, or subjects with a history of viral
hepatitis, autoimmune hepatitis, or other forms of
chronic liver disease. Moreover, subjects who were pre-
viously diagnosed as either diabetes or anemia were also
excluded. The definition of anemia in our study was
serum hemoglobin <120 g/L for males and < 110 g/L for
females. A total of 949 eligible subjects were enrolled
(603 males and 346 females, with mean age of 71.5 ±
4.5 years). Verbal informed consent was obtained from
each subject and was recorded by the physician who
explained the study procedures. Written informed con-
sent was not required because of the observational na-
ture of the study. This study protocol was approved by
the Ethics Committee of the First Affiliated Hospital,
College of Medicine, Zhejiang University, and was in
compliance with the Helsinki Declaration.
Clinical examination
The clinical examinations were performed as described
previously [16,17]. In brief, all subjects were required to
refrain from exercise for one day prior to the examin-
ation. Systolic and diastolic blood pressures were mea-
sured by standard clinical procedures. Standing height,
body weight and waist circumference were recorded for
all subjects. Waist circumference was measured with the
measuring tape positioned midway between the lowest rib
and the superior border of the iliac crest as the patient
exhaled normally. Body mass index (BMI) was calculated
as weight divided by height squared and was used as the
criteria for diagnosis of overweight and obesity.
Biochemical analyses
Fasting blood samples were obtained for the analysis of
biochemical values and HbA1c without frozen. The bio-
chemical values included liver enzymes, lipids, uric acidand glucose. All biochemical values were measured by an
Olympus AU640 autoanalyzer (Olympus, Kobe, Japan)
using standard methods. Serum HbA1c levels were
assessed by affinity chromatography method.
Diagnosis of NAFLD and the metabolic syndrome
The diagnosis of NAFLD was based on the criteria sug-
gested by the Chinese Liver Disease Association [18].
Ultrasonic examination was carried out by a trained
ultrasonographist who was unaware of the results of
physical examination and biochemical analyses. Diffuse
fatty liver can be defined by abdominal ultrasonography
with the presence of at least two of three findings below:
‘bright liver’, liver echo greater than kidney, vascular
blurring and the gradual attenuation of far field ultra-
sound echo [18]. The examination was performed by
using a Toshiba Nemio 20 sonography machine with a
3.5-MHz probe (Toshiba, Tokyo, Japan). The diagnosis
of the metabolic syndrome was based on the criteria
suggested by the new International Diabetes Federation
definition [19].
Statistical analyses
Statistical analyses were performed using SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL). The Kolmogorov-
Smirnov test was used to assess whether continuous data
were normally distributed. Continuous variables are pre-
sented as mean and standard deviation (SD) or median
and interquartile range (IQR) according to the distribu-
tion of data. Student’s t-test or the Mann–Whitney U test
was used for comparisons of continuous data, while chi-
squared test was used for comparisons of categorical vari-
ables. Adjusted regression analysis was used to investigate
the relationship between HbA1c level and prevalence of
NAFLD. Furthermore, stepwise logistic regression analysis
(Backward: Wald; Entry: 0.05, Removal: 0.10) was used to
evaluate the risk factors for NAFLD. P <0.05 (2-tailed test)
was considered statistically significant.
Results
Characteristics of study subjects
Among the 949 enrolled subjects, 257 (161 males and 96
females) met the diagnostic criteria for NAFLD; the preva-
lence of NAFLD was 27.08% (26.70% and 27.75%, in males
and females, respectively). A total of 212 subjects (22.34%)
met the diagnostic criteria for the metabolic syndrome.
The prevalence of the metabolic syndrome components,
including central obesity, hypertriglyceridemia, low HDL
cholesterol, elevated blood pressure and elevated FPG were
49.53%, 25.71%, 13.80%, 74.71% and 17.39%, respectively.
The characteristics of the subjects, classified by the pres-
ence or absence of NAFLD, were presented in Table 1.
Subjects with NAFLD had higher BMI, waist circumference,
systolic and diastolic blood pressure, γ-Glutamyltransferase,
Figure 1 Prevalence of NAFLD associated with normal range of
serum HbA1c levels. The prevalence of NAFLD was positively
correlated with increase in normal range of serum HbA1c level.
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and a lower HDL cholesterol level than subjects without
NAFLD. As noticed in Table 1, significant higher serum
HbA1c level was observed in the subjects with NAFLD
than those without NAFLD (Table 1).
Association of HbA1c level with prevalence of NAFLD
Among the 949 enrolled subjects, 68 (7.17%) had
increased serum HbA1c level (HbA1c ≥6.5%), while the
remaining 881 (92.83%) had normal range of serum
HbA1c level (HbA1c <6.5%). The prevalence of NAFLD
was much higher in the subjects with increased serum
HbA1c level than in those with normal range of serum
HbA1c level (51.71% vs. 25.20%; χ2 test, P <0.001).
To investigate whether normal range of serum HbA1c
was also associated with prevalence of NAFLD, subjects
with normal range of serum HbA1c were further divided
into quartiles as follow: quartile 1: HbA1c ≤5.4%, quar-
tile 2: 5.4% < HbA1c ≤5.6%, quartile 3: 5.6% < HbA1c
<5.9%, and quartile 4: 5.9% ≤HbA1c <6.5%. As showed
in Figure 1, the prevalence of NAFLD was positively
associated with serum HbA1c level. The prevalence of
NAFLD was 18.84% for the subjects with serum HbA1c
level in quartile 1, and the prevalence increased to
35.91% for the subjects with serum HbA1c level in quar-
tile 4 (Figure 1; P value for trend <0.01). This indicated
that change of normal range of serum HbA1c was also
associated with prevalence of NAFLD.
Independent association between HbA1c level and NAFLD
Obesity and the metabolic syndrome are two major factors
that closely associated with NAFLD, and these two factors
may act as cofactors for the link between serum HbA1c
level and NAFLD. To explore whether the associationTable 1 Characteristics of study subjects according to presen
Variables NAFLD present (n = 257)
Age (year) 71.22 (4.34)
Gender (male/female, n) 161/96
Body mass index (kg/m2) 26.79 (2.86)
Waist circumference (cm) 91.2 (8.5)
Systolic blood pressure (mmHg) 141.7 (16.9)
Diastolic blood pressure (mmHg) 81.9 (9.9)
γ-Glutamyltransferase (U/L) 27.0 (20.0 – 41.0)
Triglyceride (mmol/L) 1.60 (1.25 – 2.06)
Total cholesterol (mmol/L) 5.12 (0.98)
HDL cholesterol (mmol/L) 1.32 (0.26)
LDL cholesterol (mmol/L) 2.93 (0.85)
Fasting plasma glucose (mmol/L) 5.19 (4.75 – 5.66)
Serum uric acid (μmol/L) 363.9 (87.2)
Serum HbA1c (%) 5.80 (5.50 – 6.10)
Data are expressed as mean (SD) or median (IQR). a χ2 value; b Z value; HDL, high-dbetween serum HbA1c level and NAFLD was independent
of obesity and the metabolic syndrome, 470 subjects with
obesity and/or the metabolic syndrome were excluded for
further analysis. Among the remaining 479 lean subjects,
59 fulfilled the diagnostic criteria for NAFLD, 21 had
increased serum HbA1c level. The prevalence of NAFLD
was also significantly higher in the subjects with increased
serum HbA1c level than in those with normal range of
serum HbA1c level (28.57% vs. 11.57%; χ2 test, P =0.033).
To investigate whether normal range of serum HbA1c
was also associated with prevalence of NAFLD in lean
elderly subjects, 458 lean subjects with normal range of
serum HbA1c were further divided in to quartiles as
described above. As showed in Figure 1, the prevalence of
NAFLD was also positively correlated with serum HbA1c
level. These results not only suggested that the link be-
tween serum HbA1c level and NAFLD observed from the
general elderly population also holds true for lean elderlyce of NAFLD
NAFLD absent (n = 692) t value P value
71.55 (4.53) 1.003 0.316
442/250 0.122a 0.762
23.48 (2.67) 16.612 < 0.001
83.6 (8.1) 12.773 < 0.001
136.6 (18.2) 3.878 < 0.001
79.1 (10.3) 3.816 < 0.001
20.0 (15.0 – 28.0) 8.484 b < 0.001
1.13 (0.85 – 1.52) 10.337b < 0.001
5.14 (0.94) 0.343 0.732
1.49 (0.32) 7.532 < 0.001
3.01 (0.78) 1.392 0.164
4.92 (4.63 – 5.31) 5.225b < 0.001
327.0 (83.5) 5.976 < 0.001
5.60 (5.40 – 5.90) 5.733b < 0.001
ensity lipoprotein; LDL, low-density lipoprotein.
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not influenced by other metabolic disorders.
Serum HbA1c level and risk factor of NAFLD
Logistic regression analysis was used to evaluate the risk
factors for NAFLD. Sixteen variables, including age, gen-
der, weight, height, BMI, waist circumference, systolic and
diastolic blood pressure, γ-Glutamyltransferase, total chol-
esterol, triglyceride, HDL and LDL cholesterol, fasting
plasma glucose, serum uric acid and HbA1c level were
entered into the analysis. Linear regression was used to
evaluate the collinearity among the variables. LDL choles-
terol and total cholesterol had a high variance proportions
in this analysis indicating a high level of collinearity be-
tween these LDL cholesterol and total cholesterol. Thus
15 variables, with LDL cholesterol and total cholesterol as
a whole, were entered into the initial equation of stepwise
logistic regressions. Our result showed that age, gender,
BMI, waist circumference, γ-Glutamyltransferase, trigly-
ceride, HDL cholesterol, fasting plasma glucose, serum
uric acid and HbA1c were significantly associated with the
risk for NAFLD (Table 2). A notable finding was that
serum HbA1c level was found to be significantly asso-
ciated with risk factor for NAFLD (OR: 1.547, 95% CI:
1.054 – 2.270; P =0.026).
Discussion and conclusion
Our results showed that serum HbA1c was independently
associated with NAFLD in an elderly Chinese population.
First, serum HbA1c level was significantly increased in
NAFLD patients, and the level was positively correlated
with prevalence of NAFLD. Second, subgroup analysis
indicated that the correlation between serum HbA1c level
and NAFLD was independent of obesity and the metabolic
syndrome. Third, the result of logistic analysis showed that
increased serum HbA1c level was significantly associated
with risk factor for NAFLD.
This relationship can be explained by the following
two reasons. One of the possible explanations for theTable 2 Risk factors associated with the presence of NAFLD
Variables β SE
Age (year) −0.056 0.021
Male gender −0.779 0.241
Body mass index (kg/m2) 0.352 0.048
Waist circumference (cm) 0.035 0.017
γ-Glutamyltransferase (U/L) 0.011 0.004
Triglyceride (mmol/L) 0.523 0.121
HDL cholesterol (mmol/L) −1.589 0.379
Fasting plasma glucose (mmol/L) 0.262 0.141
Serum uric acid (mmol/L) 0.004 0.001
Serum HbA1c (%) 0.436 0.196
β, partial regression coefficient; SE, standard error of partial regression coefficient; Oincreased HbA1c in NAFLD patients is insulin resist-
ance. Insulin resistance is a central component of
NAFLD [20]. Hepatic steatosis played an important role
in the pathogenesis of insulin resistance. Recent studies
indicated that impaired hepatic lipid and lipoprotein set-
tling and increased oxidative stress in liver cells may in-
crease liver fat accumulation and result in insulin
resistance [21,22], thus increase the hepatic glucose pro-
duction and export to the peripheral circulation, as a re-
sult, raise the level of serum glucose [23]. The level of
HbA1c is influenced by lifespan and “glucose permeabil-
ity” of the erythrocytes [24]. As indicated by a recent
study, transmembrane glucose gradient rather than the
rate of glucose transport correlates with the HbA1c [25].
Based on this point, elevated HbA1c in NAFLD in this
study can be stated as the increase of intracellular glu-
cose in NAFLD patients.
The other possible mechanism by which HbA1c linked
with NAFLD is through oxidative stress. Oxidative stress
is a key pathophysiological process responsible for NAFLD
[26]. In response to oxidative stress, erythrocytes may
undergo morphology change and decreased membrane
fluidity, becoming easy to be captured by liver macro-
phages [27]. An enhanced erythrocytes susceptibility to
haemolysis was reported in an experimental model of
NAFLD and in obese subjects [28]. Immoderate haemoly-
sis will in return enhance oxidative stress [29]. As red
blood cell fragility, which influences lifespan of the ery-
throcytes, was positively correlated with glycosylated
hemoglobin [24,30], oxidative stress should be a likely
explanation.
The link between HbA1c and NAFLD may provide a
potential explanation for why NAFLD can be a risk for
cardiovascular diseases. Independent association between
NAFLD and cardiovascular disease was emphasized in
several epidemiological studies [31,32]. However, the
physiological mechanism for the link between NAFLD
and cardiovascular disease remains unclear. Since HbA1c
is indicated to be a marker of cardiovascular risk [33,34],Wald χ2 P value OR (95% CI)
7.294 0.007 0.945 (0.908 – 0.985)
10.406 0.001 0.459 (0.286 – 0.737)
53.123 <0.001 1.422 (1.293 – 1.563)
4.436 0.035 1.036 (1.002 – 1.071)
8.066 0.005 1.011 (1.003 – 1.019)
18.525 <0.001 1.686 (1.329 – 2.139)
17.609 <0.001 0.204 (0.097 – 0.429)
3.439 0.064 1.299 (0.985 – 1.713)
9.514 0.002 1.004 (1.001 – 1.006)
4.969 0.026 1.547 (1.054 – 2.270)
R, odds ratio; CI, confidence interval; HDL, high-density lipoprotein.
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in the present study may partially interpret why NAFLD
increases the risk for cardiovascular disease. According to
this view, strategies that aim at decreasing serum HbA1c
level in order to reduce risk of cardiovascular disease in
NAFLD patients may be taken into account.
Our study has several limitations. First, the diagnosis of
NAFLD was based on ultrasonographic examination.
Although ultrasonography is non-invasive, reasonably ac-
curate and widely used in epidemiological studies of
NAFLD, it is not sensitive enough to detect mild steatosis.
In addition, HbA1c cutoff points for the identification of
the severity of NAFLD can not be identified in this study.
Moreover, the question about whether or not elevated
HbA1c is a bystander, a cause or a consequence of NAFLD
is unresolved in our study. Further researches are needed
to reveal the detailed relationship and the possible
mechanisms between serum HbA1c and NAFLD.
In conclusion, our results showed that serum HbA1c
level was significantly correlated with NAFLD in elderly
Chinese. Further clarify the precise relationship may
have significant clinical implications for the diagnosis
and prevention of NAFLD by monitoring HbA1c level.
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